FY2025 · period end Dec '25 · from the 10-K filed Mar 26, 2026
Data as filed with the SEC, provided for information only — not investment advice.
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | $0.00B | $0.00B | $0.00B | — | — |
| Operating Income | negative: -$0.02B | negative: -$0.01B | negative: -$0.02B | negative: -$0.02B | negative: -$0.03B |
| Net Income | negative: -$0.01B | negative: -$0.01B | negative: -$0.01B | negative: -$0.01B | negative: -$0.04B |
| EPS (Diluted) | negative: -$1.58 | negative: -$1.16 | negative: -$2.47 | negative: -$3.65 | — |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Total Assets | $0.00B | $0.01B | $0.01B | $0.02B | $0.02B |
| Total Liabilities | — | $0.00B | $0.00B | $0.01B | $0.00B |
| Stockholders' Equity | $0.00B | $0.01B | $0.01B | $0.01B | $0.01B |
| Cash & Equivalents | $0.00B | $0.00B | $0.00B | $0.00B | $0.02B |
| Total Debt | — | — | — | — | — |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Operating Cash Flow | negative: -$0.01B | negative: -$0.01B | negative: -$0.01B | negative: -$0.01B | negative: -$0.00B |
| Capital Expenditures | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Free Cash Flow | negative: -$0.01B | negative: -$0.01B | negative: -$0.01B | negative: -$0.01B | negative: -$0.00B |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Gross Margin | 93.4% | 93.0% | 100.0% | — | — |
| Operating Margin | negative: -4350.1% | negative: -2881.6% | negative: -10439.5% | negative: -15838.1% | negative: -57191.0% |
| Net Margin | negative: -3959.4% | negative: -2239.2% | negative: -7145.2% | negative: -11037.0% | negative: -96311.5% |
| Return on Equity | negative: -320.5% | negative: -96.9% | negative: -102.7% | negative: -125.5% | negative: -410.9% |
| Return on Assets | negative: -174.1% | negative: -72.1% | negative: -71.7% | negative: -68.0% | negative: -197.3% |
| Debt / Equity | — | — | — | — | — |
Showing the most recent 5 annual periods. Get 15 years of history on the Pro plan, or full history back to 1993 plus the smart-money dataset and webhooks on Institutional.
Who is buying and selling BioRestorative Therapies, Inc. — insider transactions from Forms 3/4/5/144 and institutional ownership from 13F, 13D, and 13G filings, point-in-time stamped like every other fact in the library. Traders read it as a positioning signal; risk desks read it as concentration.
No published research on BRTX yet.
Reports appear here as analysts publish research on this company — built with Valuein's agentic workflows on data pinned to its SEC filing. Be the first: run equity_research_brief on BRTX and publish the result to your public profile.
Ask about BioRestorative Therapies, Inc.
Continue in Workspace — cited answers on BRTX, a thesis you can score, or a signal on the next filing.
Open in WorkspaceGet 15 years of data
Quarterly and annual financials back to 2011 on Pro (1993 on Institutional). Point-in-time accurate, with delisted companies kept in.
View plansQuery via Python SDK
Pull data into DuckDB with 3 lines of Python. Works in Jupyter notebooks, scripts, and CI pipelines.
SDK docsConnect via MCP Server
Wire Claude, Cursor, or Codex directly to live SEC data with a single Bearer token. No scraping, no glue code.
MCP docs| Form | Accession ID | Report Date | Filing Date | Accepted At | Source |
|---|---|---|---|---|---|
| 10-Q | 0001493152-26-023126 | Mar 31, 2026 | May 14, 2026 | May 14, 2026 20:31 UTC | EDGAR |
| 10-K | 0001493152-26-012925 | Dec 31, 2025 | Mar 26, 2026 | Mar 26, 2026 20:20 UTC | EDGAR |
| 10-Q | 0001493152-25-021993 | Sep 30, 2025 | Nov 12, 2025 | Nov 12, 2025 22:00 UTC | EDGAR |
| 10-Q | 0001641172-25-023211 | Jun 30, 2025 | Aug 12, 2025 | Aug 12, 2025 20:30 UTC | EDGAR |
| 10-Q | 0001641172-25-010299 | Mar 31, 2025 | May 14, 2025 | May 14, 2025 20:30 UTC | EDGAR |
| 10-K | 0001641172-25-001011 | Dec 31, 2024 | Mar 28, 2025 | Mar 28, 2025 01:06 UTC | EDGAR |
| 10-Q | 0001493152-24-044763 | Sep 30, 2024 | Nov 12, 2024 | Nov 12, 2024 21:15 UTC | EDGAR |
| 10-K/Aamend | 0001493152-24-043839 | Dec 31, 2023 | Nov 6, 2024 | Nov 6, 2024 21:25 UTC | EDGAR |
| 10-Q | 0001493152-24-031636 | Jun 30, 2024 | Aug 13, 2024 | Aug 13, 2024 20:30 UTC | EDGAR |
| 10-K/Aamend | 0001493152-24-023479 | Dec 31, 2023 | Jun 11, 2024 | Jun 11, 2024 20:23 UTC | EDGAR |
| 10-Q | 0001493152-24-023481 | Mar 31, 2024 | Jun 11, 2024 | Jun 11, 2024 20:28 UTC | EDGAR |
| 10-K | 0001493152-24-012056 | Dec 31, 2023 | Apr 1, 2024 | Mar 29, 2024 22:15 UTC | EDGAR |
Direct links to SEC EDGAR. BRTX has additional filings available on the SEC site.
6 numbers BioRestorative Therapies, Inc. later changed — same XBRL tag, both filings linked.
Liabilities·As of Dec 31, 2022
Major restatementwas$602.6K
Revised up in a 10-K/A.
Liabilities·As of Sep 30, 2022
Major restatementwas$915.9K
Revised up in a 10-K/A.
Liabilities·As of Jun 30, 2022
Major restatementwas$855.8K
Revised up in a 10-K/A.
Liabilities·As of Sep 30, 2023
Major restatementwas$975K
Revised up in a 10-K/A.
Liabilities·As of Dec 31, 2023
Major restatementwas$1.1M
Revised up in a 10-K.
Net Income (Loss) Attributable to Parent·Q3 2023
Major restatementwas-$3M
Revised down in a 10-Q.
BRTX is not the only one.
See every restatement we've found across the market — or get an alert the next time BRTX revises a number.
Restatements are detected by comparing every vintage of a fact across all of BioRestorative Therapies, Inc.'s filings back to 1993. A revision is not by itself a sign of wrongdoing — companies re-file for many legitimate reasons. This list is not exhaustive: it shows BRTX's most significant revisions, and a figure absent from it has not been certified as unrevised.
